Stockreport

MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders

MAIA Biotechnology, Inc.  (MAIA) 
PDF THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications and next-generation molecules continues.S [Read more]